Arsenic trioxide (ATO) and proteasome inhibitor bortezomib have been successfully applied to treat acute promyelocytic leukemia (APL) and multiple myeloma (MM), respectively. Their synergistic effects with other anticancer drugs have been widely studied. Here, we investigated the potential synergy of bortezomib and ATO on Bcr-Abl þ leukemic K562 cells. The results showed that cotreatment of bortezomib at 32 nM, a half concentration for growth arrest, and ATO at 1 lM, a dose with no significant cytotoxic effect, synergistically induced apoptosis in the cell line, followed by enhanced mitochondrial dysfunction, release of cytochrome c and apoptosis-inducing factor, caspase-3 cleavage and degradation of poly-adenosine diphosphate-ribose polymerase together with the decreased Bcr-Abl protein. These two drugs synergistically induced proteolytic activation of protein kinase Cd (PKCd) with enhanced activation of two mitogen-activated protein kinases phospho-c-Jun NH 2 -terminal kinase and p38. The specific PKCd inhibitor rottlerin markedly decreased bortezomib plus ATO-induced apoptosis, suggesting that PKCd plays an important role in bortezomib plus ATO-induced apoptosis. Moreover, apoptosis synergy of bortezomib and ATO could also be seen in some kinds of acute leukemic cell lines and primary cells. Totally, our results indicate that combined regimen of bortezomib and ATO might be a potential therapeutic remedy for the treatment of leukemia.
Introduction
Chronic myelogenous leukemia (CML) is one of myeloproliferative disorders characterized by the chromosome translocation (9;22) , which causes the generation of the Bcr-Abl fusion protein.
1,2 As a constitutively active kinase, the Bcr-Abl protein activates a number of signal transducers and transcription factors, thus leading to the antiapoptotic phenotype and resistance against conventional cytotoxic drugs of Bcr-Abl þ cells. 3, 4 Thus, the Bcr-Abl kinase was used as drug target to screen new drugs for the treatment of CML. The development of the Bcr-Abl kinase inhibitor Gleevec (imatinib mesylate; STI571) has revolutionized the treatment of CML. 5 Although Gleevec has been proved to be highly active in chronic-phase CML patients, it has a lesser extent of clinical effect in CML blast crisis. Especially, Gleevec resistance ultimately leads to disease progression. 6 In addition, rarely-seen myelodysplastic syndromes and acute leukemia developing after Gleevec therapy were also reported. 7, 8 Therefore, it still remains a high priority to develop new approaches to treat Bcr-Abl þ leukemia. Bortezomib (Velcade; PS-341), a synthetic, biologically active boronic acid dipeptide, is the first proteasome inhibitor that was approved by the US Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products for the treatment of refractory or relapsed multiple myeloma (MM). 9 This novel agent, which directly inhibits the proliferation and induces apoptosis of myeloma cells as well as abrogates paracrine tumor growth through alteration of myeloma-stromal cell interaction and nuclear factor-kB (NF-kB)-dependent cytokine secretion, has demonstrated significant antitumor activity in refractory and/or relapsed MM. 9, 10 Bortezomib is relatively well tolerated, causing manageable nonhematologic and hematologic toxicity. It also presents the potent antitumor activities on other cancer cells and murine xenograft models, as reviewed. 11, 12 In the meantime, combination of bortezomib with various agents, such as dexamethasone, DNA-damaging drugs, trastuzumab (herceptin) and tipifarnib, have been widely investigated. 13, 14 It seems that bortezomib offers great promise to overcome resistance to conventional chemotherapy. 15 More recently, bortezomib was shown to interact synergistically with cyclin-dependent kinase inhibitor flavopiridol and histone deacetylase inhibitor suberoylanilide hydroxamic acid or sodium butyrate to induce apoptosis in Bcr-Abl þ cells. 16, 17 Over the past 10 years, arsenic trioxide (As 2 O 3 , ATO) attracted wide interests for its ability to induce complete remission in most patients with acute promyelocytic leukemia (APL), mainly through apoptosis and differentiation induction. [18] [19] [20] [21] [22] Based on this exciting discovery, some reports showed that ATO or its combination with other chemotherapeutic drugs could also induce apoptosis and/or growth arrest in Bcr-Abl þ cells. [23] [24] [25] However, higher concentrations of ATO, with 10mM of the IC 50 value, 26 were used in these works. In this work, we investigated possible synergy between bortezomib and clinically relevant ATO in Bcr-Abl þ leukemia K562 cell line and other leukemic cells in general. We provided the first demonstration that bortezomib has the higher synergy in apoptosis induction with ATO at clinically achievable concentration in BcrAbl þ and some Bcr-Abl À leukemic cells, in which enhanced activation of protein kinase Cd (PKCd) plays a critical role. These finding suggest that an approach combining ATO with bortezomib warrants further investigation as a therapeutic strategy for leukemias.
Materials and methods

Cell lines
Various kinds of leukemic cell lines, including Bcr-Abl þ K562, U937, NB4, NB4-LR1, HL60, Kasumi-1, Jurkat, Raji, Namalwa and SU-DHL-4 cells, were cultured in RPMI 1640 (Sigma, St Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (Gibco BRL, Gaithersburg, MD, USA) in 5% CO 2 /95% air-humidified atmosphere at 371C. Cell lines and primary leukemic cells from bone marrow (BM) of four cases of acute myeloid leukemia (AML) patients (see below) were seeded at 2 Â 10 5 cells/ml and were treated with or without bortezomib and/or ATO in the presence or absence of PKCd-specific inhibitor rottlerin. Bortezomib (Millenium Pharmaceuticals Inc., Cambridge, MA, USA) was dissolved in phosphate-buffered saline (PBS) and stored at À201C until usage. ATO (Sigma) was dissolved in 1.0 N NaOH and then diluted to 1 mM with PBS as a stock solution. Rottlerin (BIOMOL, Plymouth, PA, USA) was prepared in ethanol as 1 mM stock solution and was kept in À201C. Cell viability was determined by the trypan-blue exclusion assay. Growth inhibition rate was evaluated by the viable cell numbers in treated cells against untreated ones.
Flow cytometry assay for apoptosis
The mitochondrial membrane potential (DCm) was performed as described previously. 27 Annexin V assay was carried out by annexin V-FITC apoptosis-detection kit I according to the manufacturer's instruction (BD, San Diego, CA, USA). Fluorescent intensities of all probes were determined by flow cytometry (Beckman Coulter, Miami, FL, USA).
Subcellular fractionation
For subcellular fractionation, K562 cells (about 1-2 Â 10 7 ) were harvested and resuspended in lysis buffer A (40 mM Tris-HCL, pH 7.4, 1% cocktail, 1 mM EDTA). Then, cells were homogenized at 41C using a glass dounce homogenizer (Fisher Scientific, Pittsburgh, PA, USA) and turned to mix lysis buffer containing buffer B (1 mM sucrose, 40 mM Tris-HCL, pH 7.4, 1% cocktail, 1 mM EDTA) and buffer A in the proportion of 3:1. The homogenate was centrifuged (1 000 g, 10 min) at 41C to pellet nuclei. The post-nuclear supernatant was centrifuged at (15 000 g, 20 min) at 41C to pellet the raw mitochondria. From the post-raw mitochondrial supernatant, the soluble cytosol proteins were precipitated with chloroform and methanol according to Klotz's method. 28 The supernatant was quantified using Bio-Rad AC DC protein assay kit (Bio-Rad, Hercules, CA, USA) and aliquoted.
Western blot
Protein extracts were loaded onto an 8-12.5% SDS-PAGE and electrophoretically transferred to nitrocellulose membranes (Amersham Biosciences, Buckinghamshire, UK). The blots were incubated with antibodies against c-Abl, PKCd, apoptosisinducible factor (AIF), cytochrome c, poly (ADP (adenosine diphosphate)-ribose) polymerase (PARP), lamin B (Santa Cruz Biotech, Santa Cruz, CA, USA), cleaved caspase-3, phospho-cJun NH 2 -terminal kinase (JNK)/total JNK, phospho-p38/p38 and cytochrome c oxidase-4 (Cell Signaling, Beverly, MA, USA). Following incubation with horseradish peroxidase (HRP)-linked secondary antibody (Cell Signaling), the signal was detected by the chemiluminescence phototope-HRP kit (Cell Signaling). As necessary, blots were stripped and reprobed with a mouse antib-actin monoclonal antibody (Oncogene, San Diego, CA, USA) as a loading control.
Patients and colony-forming unit-granulocyte macrophage assay BM samples were obtained from five cases of chronic-phase CML and four cases of AML (one case of AML-M1 and three cases of AML-M5 according to the French-American-British classification). All manipulations were consented by patients and approved by Medical Science Ethic Committee of SJTU-SM. The median age for CML patients was 44 years (range 28-58 years) and they were diagnosed according to the morphological presentation, Ph1 chromosome and positive Bcr-Abl fusion transcription on reverse transcriptase-PCR. Before CML sample collection, four patients did not receive any treatment, besides case 5 who received 2 days' hydroxyurea. Mononuclear cells were isolated by Ficoll-Hypaque centrifugation and used for clonogenic assays in methylcellulose as described previously. 29 The cells were cultured in the presence of ATO (1 mM) and/or bortezomib (8 and 16 nM). Colony-forming unit-granulocyte macrophage (CFU-GM) colonies containing at least 50 cells were scored on day 14 on an inverted phase-contrast microscope.
Statistical analysis
The significance of the difference between groups was determined by Student's t-test.
Results
Bortezomib and ATO synergistically induce growth arrest and apoptosis of K562 cells
As reported previously, 16, 23 single treatment of bortezomib or ATO dose-dependently inhibited cell growth with apoptosis induction on CML blast crisis K562 cells ( Figure 1a ). To evaluate the potential synergistic effects of these two drugs, 32 nM of bortezomib and 1 mM of ATO were selected, because this concentration of bortezomib induced half of growth inhibition with 29.870.45% apoptotic cells, while 1 mM of ATO presented no significant apoptosis-inducing effect on K562 cells. When combined treatment of bortezomib and ATO was given for 24-48 h, as depicted in Figure 1b and c, both growth inhibition and apoptosis induction were significantly enhanced, compared with treatment with either of them.
Bortezomib and ATO synergistically induce mitochondrial dysfunction and caspase-3 activation in K562 cells
It has been known that mitochondrial signaling exerts a critical role in both bortezomib-and ATO-induced apoptosis. 27, 30 Here, we also showed that 32 nM of bortezomib treatment for 48 h induced DCm collapse (Figure 2a ), followed by release of cytochrome c and AIF from mitochondria to cytosol or nuclei (Figure 2b and c) as well as caspase-3 activation and PARP fragmentation (Figure 3a) , while 1 mM of ATO failed. More intriguingly, bortezomib-induced DCm collapse, cytochrome c /AIF release and caspase-3 activation were significantly enhanced by ATO, which further supported synergistic apoptosis-inducing effect of bortezomib and ATO on K562 cells.
PKCd exerts an important role in bortezomib or bortezomib plus ATO-induced apoptosis of K562 cells
PKCd, a ubiquitously expressed member of the novel PKC family, is widely shown to contribute to apoptotic event induced by various kinds of chemotherapeutic antitumor drugs. 29, 31 Consistent with a recent report, 32 treatment with 32 nM of bortezomib alone induced proteolytic activation of PKCd to a degree (Figure 3a) . Dynamic analysis showed that the proteolytic cleavage of PKCd occurred before caspase-3 activation induced by bortezomib (Figure 3b ). In line with no significant effects of ATO at 1 mM on mitochondria, caspase-3 activation as well as apoptosis, this drug not only failed but also significantly enhanced bortezomib-induced PKCd cleavage in K562 cells (Figure 3 ). To figure out the role of PKCd in bortezomib or bortezomib plus ATO-induced apoptosis in K562 cells, 5 mM of rottlerin, a pharmacological PKCd inhibitor, 33 was used. The results showed that rottlerin almost completely blocked proteolytic activation of PKCd induced by bortezomib or bortezomib plus ATO (Figure 4a ). Accordingly, this inhibitor also eliminated bortezomib or bortezomib plus ATO-induced caspase-3 activation (data not shown) and apoptosis ( Figure 4b ). All these data indicate that active PKCd plays an important role in bortezomib or bortezomib plus ATO-induced apoptosis. (Figure 4c) . A similar phenomenon was also reported in the combined treatment of bortezomib and flavopiridol. 16 Of great interest, inhibition of PKCd activation by rottlerin also blocked the combination regimen-induced downregulation of Bcr-Abl protein (Figure 4a ).
ATO enhances bortezomib-induced activations of JNK and p38 mitogen-activated protein kinases
Previous reports showed that inhibition of JNK/p38 mitogenactivated protein (MAP) kinase enhances bortezomib-induced apoptosis of some kinds of cancer cells. [35] [36] [37] ATO at 10 mM was also reported to induce the activation of p38 and JNK with the inhibition extracellular signal-regulated kinase (ERK). 26 Consequently, we tested potential effects of bortezomib or/and ATO on these two kinases in K562 cells. As shown in Figure 5 , bortezomib (32 nM) induced JNK and p38 activations, while ATO (1 mM) only slightly activated p38, as evidenced by their phosphorylated levels. In the cotreatment of bortezomib and ATO, both JNK and p38 were greatly activated, suggesting 
Bortezomib/ATO combination significantly inhibits the clonogenic activity of fresh CML cells
We determined the effects of bortezomib and ATO on the clonogenic activity of fresh BM cells from five CML patients using CFU-GM assay. As visualized in Figure 6 , ATO (0.5 mM) or bortezomib (16 nM) alone only moderately inhibited, whereas their combined regimen significantly inhibited CFU-GM formation in all five patients, compared with their single treatments.
Apoptosis induction of the bortezomib/ATO regimen in Bcr-Abl À leukemia cells
To determine whether apoptosis synergy of bortezomib with ATO is specific to the Bcr-Abl þ leukemic cells, other Bcr-Abl bortezomib were selected for these cell lines. Thus, 4 nM of bortezomib was used for NB4-LR1, Kasumi-1 and SU-DHL-4 cells, 8 nM for NB4 and HL60, 16 nM for U937, Jurkat, Raji and Namalwa cells. Then, these cells were treated by bortezomib in the presence and absence of 1 mM ATO for 48 h. The results showed that combined treatment with bortezomib/ATO significantly enhanced apoptosis induction in NB4, NB4-LR1, Raji and SU-DHL-4 cells but not in U937, Kasumi-1, HL60, Jurkat and Namalwa cells, as determined by annexin V þ cells % (Figure 7a and b) . Moreover, apoptosis synergy of bortezomib and ATO in NB4 but not in U937 cell line could also be confirmed by PKCd/caspase-3 activation and PARP fragmentation (Figure 7c ). In addition, apoptosis synergy of bortezomib with ATO could also be clearly seen in primary leukemic cells from four cases of AML patients (Figure 7d ).
Discussion
Following the success of bortezomib in the treatment of MM, proteasome inhibitors have become a topic of interest as a novel treatment strategy for cancer. As summarized by a recent review, 38 in vitro studies demonstrated that proteasome inhibitors including bortezomib result in antileukemic activity in rapidly proliferating leukemic cell lines and in primary leukemic cells, while the normal counterparts of these cells are much more resistant to proteasome inhibitors, thereby resulting in a favorable therapeutic index. On the other hand, proteasome inhibition increases the sensitivity of cancer cells to traditional anticancer agents, such as glucocorticoids, gemcitabine, cisplatin and radiation as well as novel drugs, as described above. Recently, ongoing phase I studies are focusing on the combination of bortezomib with other cytotoxic agents, such as 17-Nallylamino-17-demethoxygeldanamycin, fludarabine, rituximab, cyclophosphamide and prednisone and some promising results were obtained. 39 In this work, we reported that bortezomib dose-dependently induced growth arrest and apoptosis in K562 cells. ATO treatment could also present the similar cellular effects on this cell line, but higher and clinically unachievable concentrations were required for its apoptosis induction. For example, ATO at 1 mM failed to induce K562 cells to undergo apoptotic cell death. More intriguingly, this concentration of ATO in combination with 32 nM of bortezomib synergistically induced a marked increase in apoptotic K562 cells, reflected by mitochondrial dysfunction, release of cytochrome c and AIF, caspase-3 cleavage and PARP fragmentation. These two drugs also significantly inhibited the clonogenic activity of fresh CML cells.
The mechanisms underlying bortezomib-or ATO-induced apoptosis have been widely investigated and multiple signaling pathways were involved, as widely reviewed. 38, 40, 41 But their exact mechanisms remain unclear. PKCd, which is regulated by proteasome degradation, enigmatically presents the multifunctional properties and is implicated in the regulation of a variety of cellular processes. Increasing lines of evidence supported a direct link between PKCd activation and apoptosis induced by diverse agents. 42 Hence, PKCd has been used as a drug target to develop new drugs for cancer therapy. Recently, Durrant et al. 32 reported that bortezomib-induced mitochondrial damage is mediated by accumulation of active PKCd. Here, we also showed that single treatment of bortezomib induced proteolytic activation of PKCd to a degree, which occurred before caspase-3 activation and apoptosis. Of great importance, although ATO at 1 mM failed to activate PKCd, its presence significantly enhanced Apoptosis synergy of bortezomib and arsenic on leukemia H Yan et al bortezomib-induced PKCd cleavage, which was in line with its enhanced effects on bortezomib-induced apoptosis. Furthermore, the PKCd inhibitor rottlerin, which almost completely blocked proteolytic activation of PKCd, significantly attenuated bortezomib or bortezomib plus ATO-induced apoptosis. All these data indicate that active PKCd plays an important role in bortezomib-induced and ATO-enhanced apoptosis of K562 cell line.
The roles of MAP kinases including JNK and p38 signaling in bortezomib-induced apoptosis were widely reported. 16, 17, 36, 37, 43 However, the significances of these kinases in ATO action were controversial. Ramos et al. 44 reported that MEK/ERK and JNK but not p38-mediated ATO(1-4 mM)-induced apoptosis in leukemia U937 cells. An important role for mitogen-and stress-activated kinase 1 downstream of p38 in the regulation of ATO responses in leukemic cells was also proposed. 45 However, ATO-induced apoptosis in HepG 2 cells was shown to be independent of MAP kinase signaling pathways. 46 Consistent to Shim's report, 26 here we showed that ATO at 1 mM slightly activated p38 but not JNK, while bortezomib activated both JNK and p38. More significantly, both JNK and p38 were greatly activated by combined treatment of bortezomib and ATO, suggesting possible contribution of these two kinases in their synergistic effect in term of apoptosis induction. It deserves to point out that our recent report showed that the activated PKCd can activate JNK. 33 Therefore, the possible relationship of bortezomib plus ATO-induced PKCd and JNK activations remains to be further investigated.
The Bcr-Abl kinase signals to multiple downstream survival pathways, including MAP kinase, Akt, signal transducers and activators of transcription, NF-kB and others. Activation of these pathways in the presence of Bcr-Abl results in the increased expression of several antiapoptotic proteins and provide cells with a survival advantage over their normal counterparts and varying degrees of resistance against conventional cytotoxic drugs.
5,34,47-49 Thus, we also tested possible alteration of BcrAbl protein under the treatment of 32 nM bortezomib and/or 1 mM of ATO. Our results showed that their single treatment had no significant impact on Bcr-Abl protein level. Nevertheless, their combined treatment could time-dependently decrease the kinase protein. Of note, this reduction appeared following PKCd activation and was blocked by inhibition of PKCd. Whether this finding proposed a link between PKCd activation and Bcr-Abl protein needs further investigation. However, it seems that increased Bcr-Abl protein did not exert a critical role even if some contributions existed. If this is the case, we hypothesized that synergistic effects of bortezomib and ATO should also appear in Bcr-Abl À leukemic cells. Indeed, such a synergy could clearly be seen in some kinds of leukemic cell lines, such as NB4, NB4-LR1, Raji and SU-DHL-4 cells, especially primary leukemic cells from four cases of AML patients. However, synergistic effects of these two drugs could not be shown in other several leukemic cells lines tested in this work, such as leukemic U937, HL60 cells and Kasumi-1 cells, although single treatment of bortezomib induced this cell line to undergo apoptosis. The reason causing this discrepancy remains to be investigated.
Collectively, this work showed that bortezomib and ATO synergistically induced apoptosis in Bcr-Abl þ K562 cells and some Bcr-Abl À leukemic cells, which was mediated by proteolytic activation of PKCd. These results indicated that combined regimen of bortezomib and ATO might be a potential therapeutic remedy for the treatment of CML and some kinds of acute leukemia and further preclinical and clinical studies should be warranted.
